Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.095
No. of companies carrying out R&D in Biotechnology;250 or more employees;103
No. of companies carrying out R&D in Biotechnology;Total 2019;1.198
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;32,4
%Companies according to biotechnology used: Genetic code;250 or more employees;42,9
%Companies according to biotechnology used: Genetic code;Total 2019;33,3
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;38,5
%Companies according to biotechnology used: Functional units;250 or more employees;54,6
%Companies according to biotechnology used: Functional units;Total 2019;39,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;23,2
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;35,1
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2019;24,2
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48
%Companies according to biotechnology used: Bioprocesses;250 or more employees;66,9
%Companies according to biotechnology used: Bioprocesses;Total 2019;49,6
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;6
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;13,9
%Companies according to biotechnology used: Sub-cellular organisms;Total 2019;6,7
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;23,9
%Companies according to biotechnology used: Bio-computing;250 or more employees;23,9
%Companies according to biotechnology used: Bio-computing;Total 2019;23,9
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;11,1
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;11,8
%Companies according to biotechnology used: Nanobiotechnology;Total 2019;11,2
%Companies according to biotechnology used: Other;Fewer than 250 employees;15,3
%Companies according to biotechnology used: Other;250 or more employees;6,9
%Companies according to biotechnology used: Other;Total 2019;14,6
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;616
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;28
Companies in which biotechnology activities are: Main and/or exclusive;Total 2019;644
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;155
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;16
Companies in which biotechnology activities are: A secondary line of business;Total 2019;171
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;324
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;59
Companies in which biotechnology activities are: A tool necessary for production;Total 2019;383
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;47,5
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;44,8
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2019;47,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;20,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;9,9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2019;19,4
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;32,1
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;37,2
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2019;32,5
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24,4
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;20,9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2019;24,1
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;14,7
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;17,6
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2019;14,9
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13,1
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;9,9
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2019;12,8
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;9.761
Personnel in R&D in biotechnology (no. of persons);250 or more employees;3.853
Personnel in R&D in biotechnology (no. of persons);Total 2019;13.615
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;5.539
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1.898
Personnel in R&D in biotechnology (no. of persons): Researchers;Total 2019;7.436
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;4.223
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1.956
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total 2019;6.178
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;5.266
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;2.373
Personnel in R&D in biotechnology (no. of persons): women;Total 2019;7.639
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.968
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;1.127
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total 2019;4.095
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;2.298
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;1.246
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total 2019;3.544
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;6.635,9
Personnel in R&D in biotechnology (FTE);250 or more employees;2.729,4
Personnel in R&D in biotechnology (FTE);Total 2019;9.365,2
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;4.020,1
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1.390,4
Personnel in R&D in biotechnology (FTE): Researchers;Total 2019;5.410,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.615,7
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1.338,9
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total 2019;3.954,6
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3.632,6
Personnel in R&D in biotechnology (FTE): women;250 or more employees;1.753,2
Personnel in R&D in biotechnology (FTE): women;Total 2019;5.385,8
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;2.192,4
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;840,5
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total 2019;3.032,9
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.440,2
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;912,6
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total 2019;2.352,9
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;677.192
Internal expenditure on R&D (thousands of euros);250 or more employees;263.038
Internal expenditure on R&D (thousands of euros);Total 2019;940.230
1) By nature of the expense: Current expenses;Fewer than 250 employees;626.080
1) By nature of the expense: Current expenses;250 or more employees;245.733
1) By nature of the expense: Current expenses;Total 2019;871.813
1.1) Remuneration to researchers;Fewer than 250 employees;200.684
1.1) Remuneration to researchers;250 or more employees;84.252
1.1) Remuneration to researchers;Total 2019;284.936
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;87.267
1.2) Remuneration to technicians and assistants;250 or more employees;60.987
1.2) Remuneration to technicians and assistants;Total 2019;148.254
1.3) Other current expenses;Fewer than 250 employees;338.128
1.3) Other current expenses;250 or more employees;100.494
1.3) Other current expenses;Total 2019;438.623
2) By nature of the expense: Capital expenses;Fewer than 250 employees;51.113
2) By nature of the expense: Capital expenses;250 or more employees;17.304
2) By nature of the expense: Capital expenses;Total 2019;68.417
2.1) Land and buildings;Fewer than 250 employees;8.402
2.1) Land and buildings;250 or more employees;3.361
2.1) Land and buildings;Total 2019;11.763
2.2) Equipment and instruments;Fewer than 250 employees;26.572
2.2) Equipment and instruments;250 or more employees;13.069
2.2) Equipment and instruments;Total 2019;39.641
2.3) Acquisition of specific R&D software;Fewer than 250 employees;2.155
2.3) Acquisition of specific R&D software;250 or more employees;676
2.3) Acquisition of specific R&D software;Total 2019;2.831
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;13.985
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;199
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2019;14.183
1.1) By origin of the funds: Own funds;Fewer than 250 employees;427.439
1.1) By origin of the funds: Own funds;250 or more employees;149.847
1.1) By origin of the funds: Own funds;Total 2019;577.287
1.2) By origin of the funds: From companies;Fewer than 250 employees;104.912
1.2) By origin of the funds: From companies;250 or more employees;37.760
1.2) By origin of the funds: From companies;Total 2019;142.672
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;81.268
1.3) By origin of the funds: Public Administration funds;250 or more employees;21.363
1.3) By origin of the funds: Public Administration funds;Total 2019;102.630
1.4) By origin of the funds: From Universities;Fewer than 250 employees;425
1.4) By origin of the funds: From Universities;250 or more employees;32
1.4) By origin of the funds: From Universities;Total 2019;457
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;2.098
1.5) By origin of the funds: From non profit private institutions;250 or more employees;7.533
1.5) By origin of the funds: From non profit private institutions;Total 2019;9.631
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;61.050
1.6) By origin of the funds: Foreign funds;250 or more employees;46.503
1.6) By origin of the funds: Foreign funds;Total 2019;107.553
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;64.508
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;50.330
Purchase of R&D services in biotechnology (thousands of euros);Total 2019;114.839
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;27.696
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;41.562
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2019;69.258
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;36.813
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;8.768
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2019;45.581
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;43,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;26,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2019;41,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;12,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;11,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2019;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;13,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2019;13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;10,6
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2019;10,7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;15,8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;8,1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2019;15,1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2019;15,7
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2019;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;38
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;31
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2019;37
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;51,7
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;40,1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2019;50,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;19,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;11,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2019;19
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;18,3
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;18,6
% Companies that have requested biotechnology patents in Biotechnology;Total 2019;18,3
Number of patents requested;Fewer than 250 employees;554
Number of patents requested;250 or more employees;89
Number of patents requested;Total 2019;643
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;25,2
% Companies with income of an international origin related to biotechnological activities;250 or more employees;16,1
% Companies with income of an international origin related to biotechnological activities;Total 2019;24,4
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;7,1
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,9
% Turnover representing income of an international origin related to biotechnological activities;Total 2019;1,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;39,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;70,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2019;55,7
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;60,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;29,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2019;44,3
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;90,9
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;50,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2019;70,3
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;4,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;41,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2019;23,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;3,2
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;7,2
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2019;5,3
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;1,1
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0,1
% Income of an international origin related with activities according to the classification: Other;Total 2019;0,6